What is Processa Pharmaceuticals?
Processa Pharmaceuticals operates in the development-stage biopharmaceutical sector, concentrating on enhancing the quality of life for patients battling severe chronic illnesses. Rather than engaging in initial drug discovery, the company strategically focuses on the development of existing pharmacological solutions, with a particular emphasis on oncology and other areas marked by substantial unmet medical needs. Their core mission is to engineer effective therapeutic options for individuals with limited or inadequate treatment choices. The company's leadership team brings a wealth of experience in regulatory science and clinical development, employing a patient-centric and de-risked methodology designed for the efficient market introduction of novel therapies.
How much funding has Processa Pharmaceuticals raised?
Processa Pharmaceuticals has raised a total of $12.9M across 3 funding rounds:
Debt
$2.6M
Debt
$150K
Share Placement
$10.2M
Debt (2017): $2.6M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Share Placement (2021): $10.2M, investors not publicly disclosed
Key Investors in Processa Pharmaceuticals
PPP
Public-Private Partnership
What's next for Processa Pharmaceuticals?
With the recent major enterprise-level funding, Processa Pharmaceuticals is poised for accelerated development and strategic expansion. This capital infusion is expected to fuel the advancement of their pipeline, potentially enabling the company to move promising therapies through critical clinical trial phases and regulatory submissions. The company's focus on developing rather than discovering treatments, coupled with their experienced leadership, suggests a strategic approach to navigating the complexities of drug commercialization. Future growth will likely involve scaling operations, forging strategic partnerships, and potentially seeking further investment to support late-stage development and market launch activities.
See full Processa Pharmaceuticals company page
